Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Blood (2024) 143 (18): 1873–1877.

https://doi.org/10.1182/blood.2023023593

Published: 2024

Includes: Supplemental data

Journal Articles

Artificial Intelligence Derived Changes between Baseline and Interim FDG-PET/CT Radiomics Features Are Associated with Survival Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Jacob Shreve, Allison M. Bock, Izel Okcu, Antonious Hazim, Joshua C Pritchett, Raphael Mwangi, Matthew J. Maurer, Mithun V Shah, Yucai Wang, Stephen M Ansell, Thomas M. Habermann, Thomas E. Witzig, James R. Cerhan, Jason R Young, Moritz Binder, Grzegorz S. Nowakowski, Jonas Paludo

Blood (2023) 142 (Supplement 1): 5026.

https://doi.org/10.1182/blood-2023-190958

Published: 2023

Journal Articles

Healthcare Utilization Outcomes of Outpatient CAR-T Cell Therapy with Remote Patient Monitoring Program

Blood (2023) 142 (Supplement 1): 5075.

https://doi.org/10.1182/blood-2023-187834

Published: 2023

Journal Articles

Outcomes of Attenuated Dose Fludarabine and Melphalan Based Conditioning Regimen in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Acute Leukemia and Myelodysplastic Syndrome

Anmol Baranwal, Radowan Elnair, Kimberly J Langer, Rami Basmaci, Jade Kutzke, Gabriel Bartoo, Robert C Wolf, Mehrdad Hefazi, Abhishek A Mangaonkar, Mithun V Shah, Mark R. Litzow, William J. Hogan, Hassan Alkhateeb

Blood (2023) 142 (Supplement 1): 3549.

https://doi.org/10.1182/blood-2023-190676

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Blood (2023) 142 (18): 1570–1575.

https://doi.org/10.1182/blood.2023021212

Published: 2023

Includes: Supplemental data

Journal Articles

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Blood (2023) 142 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2023-187860

Published: 2023

Journal Articles

Molecular Findings on Plasma Cell-Free DNA Analysis Among Adults with Histiocytic Neoplasms

Blood (2023) 142 (Supplement 1): 6332.

https://doi.org/10.1182/blood-2023-187500

Published: 2023

Journal Articles

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

Kristen McCullough, Omer Karrar, Moazah Iftikhar, Maymona Abdelmagid, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Mrinal M. Patnaik, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2023) 142 (Supplement 1): 5925.

https://doi.org/10.1182/blood-2023-182326

Published: 2023

Journal Articles

STAG2 and PHF6 : Comparison of 2 X-Linked Gene Mutations in Myeloid Neoplasms

Bahga Katamesh, Amrutha Mittapalli, Rong He, David Viswanatha, Dragan Jevremovic, Mehrdad Hefazi, Antoine Saliba, Abhishek A Mangaonkar, Kebede Begna, William J. Hogan, Naseema Gangat, Mrinal M. Patnaik, Mithun V Shah, Ayalew Tefferi, Mark R. Litzow, Hassan Alkhateeb, Aref Al-Kali

Blood (2023) 142 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2023-178244

Published: 2023

Journal Articles

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood (2023) 142 (Supplement 1): 591.

https://doi.org/10.1182/blood-2023-178837

Published: 2023

Journal Articles

Evaluation of Atrial Fibrillation Risk and Outcome after Allogeneic Transplantation Using an Artificial Intelligence ECG Algorithm and Echocardiographic Parameters in an MDS Cohort

Mario Ballerini, Michael Heckman, Launia White, Razan Mohty, Yenny Vanegas Moreno, Hassan Alkhateeb, Mohamed A. Kharfan-Dabaja, Nandita Khera, William J. Hogan, Mark R. Litzow, Abhishek A Mangaonkar, Hemant S. Murthy, Jeanne Palmer, Mithun V Shah, Lisa Sproat, Chris Ray, James M. Foran

Blood (2023) 142 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2023-183019

Published: 2023

Journal Articles

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Maymona Abdelmagid, Kaaren K. Reichard, Omer Karrar, Rong He, Patricia Greipp, Rhett Ketterling, Mithun V Shah, Devendra Hiwase, Attilio Orazi, Daniel A. Arber, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 4214.

https://doi.org/10.1182/blood-2023-183010

Published: 2023

Journal Articles

The Peripheral Blood Stem Cell Immunome Demonstrates Abnormal Immune Effector Cells Early in the Disease Course of Multiple Myeloma and Contributes to Inferior Outcomes and Secondary Myeloid Neoplasms

Saurabh Zanwar, Eapen K. Jacob, Carl Greiner, Kevin Pavelko, Michael Strausbauch, Emilie Anderson, Arini Arsana, Megan Weivoda, Mithun V Shah, Taxiarchis Kourelis

Blood (2023) 142 (Supplement 1): 90.

https://doi.org/10.1182/blood-2023-174286

Published: 2023

Journal Articles

Cardiovascular Morbidity in Erdheim-Chester Disease (ECD) Patients with and without Cardiac Involvement

Reema K Tawfiq, Jason R Young, Madeline Mahowald, Saurabh Zanwar, Gordon J Ruan, Karen L Rech, Matthew J Koster, Lucinda Gruber, Aishwarya Ravindran, Mithun V Shah, N. Nora Bennani, Robert Vassallo, Jay Ryu, Caroline Davidge-Pitts, Surendra Dasari, Thomas E. Witzig, Ronald S. Go, Gaurav Goyal, Jithma Prasad Abeykoon

Blood (2023) 142 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2023-180322

Published: 2023

Journal Articles

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Lih En Hong, Chung Hoow Kok, Monika Kutyna, Joule J Li, Rakchha Chhetri, David M. Ross, Susan Branford, Hamish S Scott, Anna Brown, Christopher Norman Hahn, David T Yeung, Mrinal M. Patnaik, Mithun V Shah, Susanna Proudman, Mihir Wechalekar, Devendra Hiwase

Blood (2023) 142 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2023-190809

Published: 2023

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

T-Cells Immune Cluster Analysis Using Cytof Identifies Unique Patient Subgroups with TP53 Mutation and Predicts Complete Remission (CR) in Patients with Acute Myeloid Leukemia (AML) Receiving Venetoclax Plus Hypomethylating Agent Therapy

Talha Badar, Keith Knutson, James M. Foran, Naseema Gangat, Kevin Pavelko, Scott H. Kaufmann, Mark R. Litzow, Hemant S. Murthy, Davitte Cogen, Margaret Ushman, Arini Arsana, Aref Al-Kali, Hassan Alkhateeb, Ayalew Tefferi, Mrinal M. Patnaik, Mithun V Shah

Blood (2023) 142 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2023-185654

Published: 2023

Journal Articles

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Animesh D. Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Cecilia Y. Arana Yi, Ayalew Tefferi, Naseema Gangat

Blood (2023) 142 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2023-185185

Published: 2023

Journal Articles

Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2023-184911

Published: 2023

NARROW

IDH -mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Artificial Intelligence Derived Changes between Baseline and Interim FDG-PET/CT Radiomics Features Are Associated with Survival Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Healthcare Utilization Outcomes of Outpatient CAR-T Cell Therapy with Remote Patient Monitoring Program

Outcomes of Attenuated Dose Fludarabine and Melphalan Based Conditioning Regimen in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Acute Leukemia and Myelodysplastic Syndrome

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Molecular Findings on Plasma Cell-Free DNA Analysis Among Adults with Histiocytic Neoplasms

ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

STAG2 and PHF6 : Comparison of 2 X-Linked Gene Mutations in Myeloid Neoplasms

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Evaluation of Atrial Fibrillation Risk and Outcome after Allogeneic Transplantation Using an Artificial Intelligence ECG Algorithm and Echocardiographic Parameters in an MDS Cohort

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

The Peripheral Blood Stem Cell Immunome Demonstrates Abnormal Immune Effector Cells Early in the Disease Course of Multiple Myeloma and Contributes to Inferior Outcomes and Secondary Myeloid Neoplasms

Cardiovascular Morbidity in Erdheim-Chester Disease (ECD) Patients with and without Cardiac Involvement

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

T-Cells Immune Cluster Analysis Using Cytof Identifies Unique Patient Subgroups with TP53 Mutation and Predicts Complete Remission (CR) in Patients with Acute Myeloid Leukemia (AML) Receiving Venetoclax Plus Hypomethylating Agent Therapy

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only